<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Chronic allograft nephropathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Chronic allograft nephropathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Chronic allograft nephropathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14609957"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney allograft failure is one of the most common causes of end-stage kidney disease (ESKD), accounting for 25 to 30 percent of patients awaiting kidney transplantation. Similarly, over 20 percent of kidney transplantations performed in the United States go to patients who have failed one of more kidney allografts.</p><p>The most common cause of graft failure after the first year is an incompletely understood clinicopathological entity called chronic allograft nephropathy (CAN; also called interstitial fibrosis/tubular atrophy [IF/TA]). CAN is a histopathological description, rather than a specific disease entity, that refers to the features of chronic interstitial fibrosis and tubular atrophy within the kidney allograft. It has previously been called chronic rejection, transplant nephropathy, chronic allograft dysfunction, transplant glomerulopathy (TG), or chronic allograft injury.</p><p>This topic will review the pathogenesis, pathology, diagnosis, and management of CAN. Other aspects related to kidney allograft failure and the evaluation of kidney allograft dysfunction are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7320.html" rel="external">"Kidney transplantation in adults: Management of the patient with a failed kidney transplant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p></p><p class="headingAnchor" id="H3894909563"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic allograft nephropathy (CAN)</strong> – CAN is a histopathologic description, rather than a specific disease entity, that refers to the features of chronic interstitial fibrosis and tubular atrophy within the kidney allograft.</p><p></p><p class="bulletIndent1">The term "CAN" was originally introduced in 1991 by the Banff working classification to replace the then-popular and misleading term "chronic rejection" [<a href="#rid1">1</a>]. The intention was to reverse the misconception that all late scarring of the allograft was caused by alloimmune injury/rejection. However, subsequent use of the term CAN in the transplant literature promoted the misconception that CAN was a specific disease, rather than a pathologic description for nonspecific kidney parenchymal scarring. Furthermore, the use of CAN as a generic term for all causes of chronic allograft dysfunction with fibrosis was thought to diminish attempts to determine the underlying cause of the histologic lesions, some of which could be amenable to treatment.</p><p></p><p class="bulletIndent1">Consequently, the revised Banff 2005 classification system replaced CAN with "interstitial fibrosis and tubular atrophy (IF/TA), without evidence of any specific etiology" [<a href="#rid2">2</a>]. This was done to differentiate specific diagnostic entities (such as chronic active antibody-mediated rejection [ABMR], chronic active T cell-mediated rejection [TCMR], calcineurin inhibitor [CNI] toxicity, and BK polyomavirus [BKPyV]-associated nephropathy) from a nonspecific fibrotic subtype of CAN. However, the newer term IF/TA is no more or less disease specific than CAN. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Chronic rejection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic allograft dysfunction</strong> – Chronic allograft dysfunction is defined as a clinical condition characterized by a slow (over a period of months to years), progressive decrease in kidney function, usually associated with hypertension and worsening proteinuria. Chronic allograft dysfunction may result from a number of different causes, including CAN, recurrent and de novo glomerulonephritis, BKPyV-associated nephropathy, late or recurrent acute rejection, renal artery stenosis, and occasionally, ureteric obstruction.</p><p></p><p class="headingAnchor" id="H3463449564"><span class="h1">RISK FACTORS FOR CHRONIC ALLOGRAFT INJURY</span><span class="headingEndMark"> — </span>Multiple factors, both alloantigen dependent as well as alloantigen independent, appear to contribute to the pathogenesis of chronic graft dysfunction [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H1354996759"><span class="h2">Alloantigen-dependent factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection</strong> – Acute rejection is a strong risk factor for the development of chronic allograft nephropathy (CAN). The incidence of CAN is &lt;1 percent in patients who have had no episodes of acute rejection. By comparison, the incidence of CAN is increased in patients with a history of acute rejection: 20 percent for living-related and 36 percent for cadaver kidneys, if acute rejection occurred within 60 days after transplantation, and 43 percent for living-related and 60 percent for cadaver kidneys, if acute rejection occurred more than 60 days posttransplantation [<a href="#rid5">5,6</a>]. The risk of CAN is higher in those with multiple episodes of acute rejection, late rejection episodes (occurring &gt;6 months after transplantation), and increased severity of the acute rejection episodes [<a href="#rid5">5-8</a>]. (See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure", section on 'Episodes of acute rejection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive regimens</strong> – Adequate levels of immunosuppression help prevent acute, subclinical, and/or chronic immunologic rejection, thereby providing some protection against the development of CAN. However, some immunosuppressive agents, particularly calcineurin inhibitors (CNIs), may also be associated with impaired long-term allograft function, which is frequently difficult if not impossible to distinguish from CAN. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="headingAnchor" id="H2855142267"><span class="h2">Alloantigen-independent factors</span><span class="headingEndMark"> — </span>There are also alloantigen-independent mechanisms that can promote chronic injury and poor function in the kidney allograft. These include the following [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular hyperfiltration and hypertrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Superimposed recurrent or de novo kidney parenchymal disease</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed graft function</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia</p><p></p><p>Additional factors for graft failure, including donor and recipient characteristics, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure"</a>.)</p><p class="headingAnchor" id="H1992205525"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H2325923701"><span class="h2">Characteristic findings</span><span class="headingEndMark"> — </span>Histologically, chronic allograft nephropathy (CAN) is characterized by the presence of interstitial fibrosis and tubular atrophy (IF/TA) [<a href="#rid10">10-13</a>]. The pathologic changes may also involve the blood vessels and glomeruli.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitium/tubules</strong> – The interstitium shows variable degrees of patchy fibrosis and focal cellular infiltrates with lymphocytes and plasma cells, associated with a variable degree of tubular atrophy and tubular cell dropout. These nonspecific findings are also found to varying degrees with many disorders, particularly calcineurin inhibitor (CNI) nephrotoxicity [<a href="#rid14">14</a>]. The severity of CAN can be graded according to the amount of interstitial fibrosis and the degree of atrophy and loss of tubules [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood vessels</strong> – The vessel walls are thickened by the subintimal accumulation of loose and then organized connective tissue, variable mononuclear cellular infiltration, proliferation of myofibroblasts, and disruption and duplication of the internal elastic lamina  (<a class="graphic graphic_picture graphicRef72574 graphicRef52555 graphicRef65391" href="/z/d/graphic/72574.html" rel="external">picture 1A-C</a>). It has been proposed that endothelial inflammation and injury may be one of the primary events, leading to progressive intimal thickening and narrowing of the vascular lumen [<a href="#rid12">12</a>]. These changes are similar to those seen in the thrombotic microangiopathies. (See  <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glomeruli</strong> – The glomerular capillary walls are thickened with an occasional double-contour appearance, resembling that seen in membranoproliferative glomerulonephritis (MPGN) but without dense deposits. The glomeruli may also be enlarged and show a lobular pattern; segmental or, in severe cases, global sclerosis also may be seen. Electron microscopy may show mesangial cell interposition and subendothelial accumulation of electron-lucent material  (<a class="graphic graphic_picture graphicRef58239 graphicRef79914" href="/z/d/graphic/58239.html" rel="external">picture 2A-B</a>). Immune complex deposition is generally not a feature.</p><p></p><p class="headingAnchor" id="H1456448433"><span class="h2">Natural history of CAN</span><span class="headingEndMark"> — </span>Insight into the natural history of chronic allograft nephropathy (CAN) was provided by a study of 120 kidney-pancreas transplant recipients who underwent sequential protocol biopsies over a 10-year posttransplantation period [<a href="#rid15">15</a>]. Based upon the time posttransplantation, two types of histologic injury, early and late, could be distinguished:</p><p class="bulletIndent1"><span class="glyph">●</span>Early damage, which was observed within one year posttransplantation, resulted primarily from immunologic factors, such as severe acute rejection and persistent early subclinical rejection, as well as from ischemic injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After one year, damage was characterized by progressive high-grade arteriolar hyalinosis, with vessel narrowing, glomerulosclerosis, and additional tubulointerstitial injury. This was thought to principally be the result of CNI injury. By comparison, chronic immune rejection was uncommon with prolonged follow-up.</p><p></p><p>After 10 years, severe allograft nephropathy was present in 60 percent of patients, with glomerulosclerosis being observed in almost 40 percent of glomeruli. These findings suggest that different treatment strategies for CAN, based in part upon time posttransplantation (prevention of rejection in the first year and, in stable patients, limiting CNI exposure in the subsequent years), may prove effective.</p><p>However, a subsequent study of adult recipients of solitary kidney transplants between 1998 and 2004 suggested that severe histologic changes are not common in the first five years after transplantation [<a href="#rid16">16</a>]. The disparity in severity of histologic lesions observed in these two studies may reflect differences in the rate of acute rejection incurred in simultaneous kidney-pancreas transplants performed in an earlier immunosuppressive era using higher levels of primarily cyclosporine-based immunosuppression compared with more recent solitary kidney transplants, or reflect complications from chronic dehydration or recurrent urinary tract infections caused by a bladder-drained pancreas in the kidney-pancreas transplants.</p><p class="headingAnchor" id="H2412653797"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1856388846"><span class="h2">When to suspect CAN</span><span class="headingEndMark"> — </span>Chronic allograft nephropathy (CAN) should be suspected in any kidney transplant recipient who presents with chronic allograft dysfunction (ie, slow, progressive decrease in kidney function, usually associated with hypertension and worsening proteinuria).</p><p class="headingAnchor" id="H3692627261"><span class="h2">Evaluation of chronic allograft dysfunction</span><span class="headingEndMark"> — </span>In kidney transplant recipients who present with chronic allograft dysfunction, the goal of the diagnostic evaluation is to identify the potential cause(s) of progressive kidney dysfunction. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We obtain a kidney ultrasound with Dopplers of the renal artery, to assess size and echogenicity of the allograft and to potentially exclude renal artery stenosis. (See  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation", section on 'Evaluation for transplant renal artery stenosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We estimate proteinuria by determining a spot urine protein-to-creatinine ratio. If the patient has confirmed proteinuria &gt;1 g/day, we perform a kidney allograft biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We assess for the presence and strength/titers of donor-specific antibodies (DSAs). (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We assess for the presence of BK polyomavirus (BKPyV) by measuring a blood BKPyV viral load. (See  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy", section on 'Screening and diagnosis'</a>.)</p><p></p><p>There is substantial variability among transplant centers regarding obtaining biopsy material for histologic analysis. It is the view of the authors that allograft histology is useful for confirming the diagnosis and also to rule out other processes, such as acute rejection or recurrent glomerulonephritis (see <a class="local">'Differential diagnosis'</a> below). In addition, a percutaneous allograft biopsy provides prognostic information that assists in patient counseling.</p><p class="headingAnchor" id="H1502082946"><span class="h2">Evaluation of IF/TA</span><span class="headingEndMark"> — </span>The severity of CAN can be graded semi-quantitatively according to the amount of interstitial fibrosis and the degree of atrophy and loss of tubules (IF/TA) present on kidney allograft biopsy [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade I – Mild fibrosis of the interstitium (ie, affecting 6 to 25 percent of the cortical area) and mild atrophy of the tubules (ie, up to 25 percent of the area of the cortical tubules)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade II – Moderate interstitial fibrosis (ie, affecting 25 to 50 percent of the cortical area) and moderate tubular atrophy (ie, involving 26 to 50 percent of the area of the cortical tubules)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade III – Severe interstitial fibrosis (ie, affecting &gt;50 percent of the cortical area) and tubular atrophy (ie, involving &gt;50 percent of the area of the cortical tubules)</p><p></p><p class="headingAnchor" id="H2953121956"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of chronic allograft nephropathy (CAN) involves distinguishing among the many factors that cause progressive allograft dysfunction and/or are associated with similar histologic findings. (See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p class="headingAnchor" id="H2828458541"><span class="h2">Progressive allograft dysfunction</span><span class="headingEndMark"> — </span>Other than CAN, the principal causes of chronic kidney allograft dysfunction include chronic antibody-mediated rejection (ABMR), diabetic kidney disease (recurrent or de novo), recurrent or de novo glomerulonephritis, BK polyomavirus (BKPyV)-associated nephropathy, late acute rejection, and renal artery stenosis [<a href="#rid17">17,18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic antibody-mediated rejection</strong> – Chronic ABMR, one of the most common causes of chronic graft failure, may present similarly to CAN with slowly progressive graft dysfunction [<a href="#rid19">19</a>]. It can be differentiated from CAN histologically by the presence of C4d staining in the peritubular capillaries, which is absent in patients with CAN. Positive testing for donor-specific antibodies (DSAs) also supports the diagnosis of chronic ABMR and excludes the diagnosis of CAN. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Chronic rejection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetic kidney disease</strong> – Recurrent or de novo diabetic kidney disease may be a cause of progressive allograft dysfunction among kidney transplant recipients with diabetes. Diabetic kidney disease can be differentiated from CAN by the presence of characteristic histologic findings such as mesangial expansion, which can be diffuse or nodular (often termed "Kimmelstiel-Wilson nodules"), and glomerular sclerosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent or de novo glomerulonephritis</strong> – Recurrent or de novo glomerular disease can lead to progressive allograft dysfunction and long-term allograft loss [<a href="#rid20">20</a>]. A previous history of biopsy-confirmed glomerular disease in the native kidneys as well as findings on allograft kidney biopsy help to distinguish recurrent glomerular disease from CAN. De novo glomerulonephritis after kidney transplantation, most commonly caused by immunoglobulin A (IgA) nephropathy or an immune complex glomerulonephritis, is also diagnosed by kidney allograft biopsy. It is important that immunofluorescence and electron microscopy of allograft biopsy material be performed if such diagnoses are under consideration. (See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure", section on 'Recurrent or de novo glomerular disease'</a> and  <a class="medical medical_review" href="/z/d/html/7344.html" rel="external">"IgA nephropathy: Recurrence after transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7343.html" rel="external">"Membranoproliferative glomerulonephritis: Recurrence of idiopathic disease after transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7341.html" rel="external">"Membranous nephropathy and kidney transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/96663.html" rel="external">"C3 glomerulopathies: Recurrence after transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BK polyomavirus-associated nephropathy</strong> – BKPyV-associated nephropathy typically presents with subacutely progressive allograft dysfunction. The diagnosis may be suggested by the presence of the virus in blood (or urine) by polymerase chain reaction (PCR). The diagnosis of BKPyV-associated nephropathy is established by specific findings on allograft biopsy, particularly results with immunohistochemical staining and/or ultrastructural examination of the specimen by electron microscopy. (See  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late or recurrent acute rejection</strong> – Late or recurrent acute rejection, commonly occurring as a result of nonadherence to immunosuppressive medications or underimmunosuppression resulting from intentional weaning of immunosuppression by clinicians, may present with kidney allograft dysfunction. Acute allograft rejection, which is diagnosed by characteristic histologic findings, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal artery stenosis</strong> – The administration of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) to a patient with transplant renal artery stenosis can lead to a reversible decline in glomerular filtration rate (GFR). Thus, an elevation in plasma creatinine concentration in this setting is suggestive, but not diagnostic, of renovascular disease in the allograft. Persistent uncontrolled hypertension, flash pulmonary edema, and an acute elevation in blood pressure are other common features of this disorder. The diagnosis of renal artery stenosis is based on findings with imaging studies. (See  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2814822439"><span class="h2">Similar histologic findings</span><span class="headingEndMark"> — </span>CAN must primarily be distinguished histologically from those disorders that can cause a predominant interstitial fibrosis and/or a membranoproliferative glomerulonephritis (MPGN) pattern on kidney biopsy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial fibrosis</strong> – The presence of marked interstitial fibrosis due to CAN must be differentiated from other causes of fibrosis, particularly the typical "striped fibrosis" induced by calcineurin inhibitors (CNIs; eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>). In this setting, histologic evidence of the characteristic glomerulopathy or the presence of peritubular capillary basement membrane splitting and lamination is most consistent with CAN. By comparison, the detection of newly formed hyaline arteriolar changes is specific for cyclosporine nephrotoxicity [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">However, CAN is not always associated with these characteristic findings, and the arteriolar changes suggestive of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> disease may not be new. It is therefore frequently difficult if not impossible to distinguish between these two possibilities, based upon the results of microscopy alone. Some individuals also have pathologic changes resulting from both disorders. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Membranoproliferative glomerulonephritis</strong> – The MPGN pattern of transplant glomerulopathy (TG) must be distinguished from other glomerular disorders, particularly MPGN that is associated with hepatitis C virus (HCV) infection or is due to recurrent or de novo disease. These disorders may appear similar on light microscopy.</p><p></p><p class="bulletIndent1">The distinction is made on electron microscopy, which typically shows thickening and duplication of the glomerular basement membranes without immune deposits in TG; by comparison, there are prominent subendothelial immune deposits in HCV-associated MPGN [<a href="#rid21">21</a>]. HCV positivity alone is not sufficient to make the distinction, since it may be present concurrently in patients with CAN. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H2802177520"><span class="h1">PREVENTION AND TREATMENT</span><span class="headingEndMark"> — </span>The prevention and treatment of chronic allograft nephropathy (CAN) remain two of the major challenges facing transplant nephrologists [<a href="#rid3">3,22-25</a>]. As previously mentioned, findings concerning the time dependence of various factors (see <a class="local">'Natural history of CAN'</a> above) suggest that different prevention and management strategies for CAN, based in part upon time posttransplantation, may be beneficial [<a href="#rid15">15</a>]. In the first year, for example, attention may generally be directed at the prevention of rejection, and in subsequent years among stable patients, management may focus upon limiting exposure to calcineurin inhibitors (CNIs). However, there is <strong>no</strong> effective therapy available for established CAN, and all patients inevitably progress to end-stage kidney disease (ESKD).</p><p class="headingAnchor" id="H316697675"><span class="h2">Prevention of rejection</span><span class="headingEndMark"> — </span>Given that multiple studies have documented the importance of acute rejection episodes in CAN, general measures aimed at preventing these episodes, especially in the first year posttransplantation, should help prevent the development of chronic allograft dysfunction. (See <a class="local">'Alloantigen-dependent factors'</a> above.)</p><p>We treat patients with triple maintenance immunosuppressive therapy, aiming for a regimen that includes a CNI (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is the agent most commonly used in the United States, although <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is still used occasionally), <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and an antimetabolite. Despite the possible increased risk of CAN due to CNI therapy with this approach, we feel that the immunosuppressive benefits of this regimen outweigh its possible adverse effects. General discussions of induction and maintenance immunosuppressive therapy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p>Additional preventive measures include optimizing human leukocyte antigen (HLA) matching, reducing ischemic injury (which increases proinflammatory cytokines and others), and avoiding sensitization. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7355.html" rel="external">"Kidney transplantation in adults: HLA matching and outcomes"</a> and  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>.)</p><p class="headingAnchor" id="H3601118232"><span class="h2">Modification of immunosuppression</span><span class="headingEndMark"> — </span>Several different immunosuppressive approaches and alterations in regimens have been evaluated to limit the risk of developing or aggravating CAN. These include regimens with or without CNIs, the addition or substitution of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (such as <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>), substitution of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) for <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and others. However, changes in immunosuppressive therapy have largely been ineffective in changing the prognosis for patients with established CAN.</p><p class="headingAnchor" id="H2283840180"><span class="h3">Reducing calcineurin inhibitor exposure</span><span class="headingEndMark"> — </span>Among patients with established CAN receiving CNIs, some evidence suggests that a decrease of such therapy may be effective at preventing progressive kidney dysfunction. For patients with established CAN who are receiving triple immunosuppressive therapy with a CNI, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and an antimetabolite, we suggest minimization of CNI therapy (using a lower-than-standard dose) rather than withdrawal (gradual elimination of the CNI) or conversion (switching from a CNI to an alternate immunosuppressive agent) of CNI therapy. We minimize CNI therapy by targeting lower trough levels (such as 3.5 to 5 ng/mL for <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and 75 to 125 ng/mL for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>). Withdrawal of the CNI has been shown to be associated with more acute rejection and the development of donor-specific antibodies (DSAs) and is <strong>not</strong> recommended [<a href="#rid26">26,27</a>].</p><p>A 2016 meta-analysis of 88 randomized controlled trials evaluated the outcomes of four different strategies to limiting exposure to CNIs, including minimization (using a lower-than-standard dose of CNI), conversion (switching from a CNI to an alternate immunosuppressive agent after transplantation), withdrawal (gradual elimination of the CNI after transplantation), and avoidance (avoiding the use of CNI from the time of transplantation) [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Minimization of CNIs, when combined with MMF, resulted in better kidney function, a lower risk of biopsy-proven acute rejection (relative risk [RR] 0.84, 95% CI 0.75-0.95), and a lower rate of graft loss (RR 0.76, 95% CI 0.61-0.94). However, minimization of CNIs, when combined with mTOR inhibitors, had no effect on rates of acute rejection or graft loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversion strategies had no effect on any endpoint studied; withdrawal strategies increased the risk of acute rejection (RRs of 3.17 and 1.71 for mycophenolate-based and mTOR inhibitor-based regimens, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nine trials examined avoidance strategies using a variety of replacement immunosuppressive agents (ie, <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>, mTOR inhibitors). In general, avoidance strategies did not provide any benefit. One additional trial that was not included in the meta-analysis reached a similar conclusion [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H872194401"><span class="h3">Cyclosporine versus tacrolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> is the most commonly used CNI among kidney transplant recipients in the United States, although <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is still occasionally used. Registry and limited clinical trial data indicate similar long-term patient and graft survival rates for patients on tacrolimus and cyclosporine. In patients with established CAN who are taking cyclosporine, we do not routinely switch them to tacrolimus, since conversion from cyclosporine to tacrolimus has not been shown to prevent progression of CAN.</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 150 kidney transplant recipients were randomly assigned to one of three maintenance immunosuppressive regimens: <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> plus <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, tacrolimus plus MMF, or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> plus sirolimus [<a href="#rid29">29-31</a>]. All patients received induction therapy with daclizumab and maintenance therapy with <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>. Patient and allograft survival were similar in all three groups at three years [<a href="#rid31">31</a>]. There was a trend toward better allograft function and fewer acute rejections with tacrolimus plus MMF, which was also associated with a significantly decreased incidence of posttransplantation diabetes mellitus and dyslipidemia. Similar findings showing better protection from chronic allograft dysfunction with a tacrolimus-based regimen than with a cyclosporine-based regimen were reported in an observational protocol biopsy study [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, other studies have shown that conversion from <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> does not decrease the progression of CAN. In one trial, 106 cyclosporine-treated patients with biopsy-proven CAN and impaired kidney function were randomly assigned to convert to tacrolimus or continue on cyclosporine therapy [<a href="#rid33">33</a>]. At five years, allograft survival was the same in both groups (73 and 81 percent for the tacrolimus and cyclosporine groups, respectively).</p><p></p><p class="headingAnchor" id="H3326145066"><span class="h3">Use of mycophenolate mofetil</span><span class="headingEndMark"> — </span>Another general strategy is the use of MMF rather than <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, either for prevention or as treatment of established CAN. For patients with established CAN who are receiving azathioprine as part of their maintenance immunosuppression, we suggest switching to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> rather than continuing azathioprine. The substitution of MMF, if not being administered, for azathioprine may help to ameliorate progressive kidney dysfunction. As an example, in one study, the initial immunosuppressive regimens of 121 patients with biopsy-proven CAN were either <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (59 patients) or cyclosporine and prednisone plus azathioprine (62 patients) [<a href="#rid34">34</a>]. If being administered, azathioprine was terminated, and all patients were subsequently given MMF (2 grams per day). At a median follow-up of 36 months, the change in the glomerular filtration rate (GFR) slope was significantly better with MMF (+0.00045 versus -0.0144).</p><p>Benefits may also be observed in CNI minimization strategies in which MMF is used in combination with the CNI. (See <a class="local">'Reducing calcineurin inhibitor exposure'</a> above.)</p><p class="headingAnchor" id="H3232555693"><span class="h3">Withdrawal of glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoid withdrawal to prevent CAN is <strong>not</strong> advised, as it has been associated with an increased risk of CAN. In a randomized controlled trial comparing early glucocorticoid withdrawal with low-dose, long-term glucocorticoid therapy (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 mg daily) in kidney transplant recipients receiving modern maintenance immunosuppression therapy, both rates of biopsy-proven acute rejection (18 versus 11 percent) and CAN (10 versus 4 percent) were higher in the glucocorticoid withdrawal group, although CAN was not a predefined endpoint in the study [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2415501855"><span class="h2">Other supportive measures</span><span class="headingEndMark"> — </span>Other supportive measures to help prevent the development of CAN include aggressive control of blood pressure and hyperlipidemia. These issues are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">"Lipid abnormalities after kidney transplantation"</a>.)</p><p>With respect to blood pressure control and protection of kidney allograft function, it remains unclear if angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) provide special benefit by preferential lowering the intraglomerular pressure or other effects. Clinicians have generally been reluctant to use these agents in kidney transplant recipients because of the increased risk of hyperkalemia and decreased perfusion in a single kidney. A systematic review of 21 randomized trials with 1549 patients evaluating the effects of ACE inhibitors or ARBs in kidney transplant recipients found that there were inadequate data available to assess the effects on allograft and patient survival [<a href="#rid36">36</a>]; none of these trials specifically included patients with CAN. Retrospective studies have reported conflicting results on allograft and patient survival [<a href="#rid37">37,38</a>]. In patients with CAN, some retrospective studies suggest a possible benefit with ACE inhibitors or ARBs in slowing the rate of decline in kidney function [<a href="#rid39">39-41</a>]. (See  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation", section on 'Additional agents for uncontrolled hypertension'</a>.)</p><p>Although reversing metabolic acidosis may slow the progression of CKD in nontransplant patients, there have been no studies reported in kidney transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease", section on 'Slowing of CKD progression'</a>.)</p><p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to slow kidney disease progression in nontransplant patients with proteinuric CKD, but similar studies in kidney transplant recipients are lacking. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>.)</p><p>Other therapeutic modalities, including antiplatelet agents, thromboxane antagonists, fish oil, and dietary protein restriction, have not been proven to be effective in human trials and have largely been abandoned. </p><p class="headingAnchor" id="H3704964180"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>There may be an emerging role for gene expression profiling of peripheral blood or kidney allograft biopsy tissue to identify patients who are at greater risk of fibrosis and allograft loss and who may benefit from therapeutic strategies to prevent the progression to fibrosis [<a href="#rid42">42,43</a>]. This issue is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7325.html" rel="external">"Investigational methods in the diagnosis of acute kidney allograft rejection", section on 'The molecular microscope'</a>.)</p><p class="headingAnchor" id="H3144766700"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The most common cause of kidney allograft failure after the first year is an incompletely understood clinicopathological entity called chronic allograft nephropathy (CAN; also called interstitial fibrosis/tubular atrophy [IF/TA]). CAN is a histopathological description, rather than a specific disease entity, that refers to the features of chronic interstitial fibrosis and tubular atrophy within the kidney allograft. It has previously been called chronic rejection, transplant nephropathy, chronic allograft dysfunction, transplant glomerulopathy (TG), or chronic allograft injury. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Multiple factors, both alloantigen dependent (such as acute rejection and immunosuppressive agents, particularly calcineurin inhibitors [CNIs]) as well as alloantigen independent, appear to contribute to the pathogenesis of chronic graft dysfunction. (See <a class="local">'Risk factors for chronic allograft injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Histologically, CAN is characterized by the presence of IF/TA. The pathologic changes may also involve the blood vessels and glomeruli. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – CAN should be suspected in any kidney transplant recipient who presents with chronic allograft dysfunction (ie, slow, progressive decrease in kidney function, usually associated with hypertension and worsening proteinuria). In kidney transplant recipients who present with chronic allograft dysfunction, the goal of the diagnostic evaluation is to identify the potential cause(s) of progressive kidney dysfunction. We obtain a kidney ultrasound with Dopplers of the renal artery and estimate proteinuria by determining a spot urine protein-to-creatinine ratio. In addition, we assess for the presence of donor-specific antibodies (DSAs) and BK polyomavirus (BKPyV). We perform an allograft biopsy in patients with proteinuria &gt;1 g/day to confirm the diagnosis, exclude other potential causes, and provide prognostic information. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment</strong> – The prevention and management of CAN remain two of the major challenges facing transplant nephrologists. The time dependence of various risk factors suggest that different prevention and management strategies for CAN, based in part upon time posttransplantation, may be beneficial. In the first year, for example, attention may generally be directed at the prevention of rejection, and in subsequent years among stable patients, management may focus upon limiting exposure to CNIs. However, there is <strong>no</strong> effective therapy available for established CAN, and all patients inevitably progress to end-stage kidney disease (ESKD).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To prevent general immunologic rejection, we maintain patients with triple immunosuppressive therapy, aiming for a regimen that includes a CNI, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and an antimetabolite. Despite the possible increased risk of CAN due to CNI therapy, we feel that the immunosuppressive benefits outweigh its possible adverse effects. (See <a class="local">'Prevention of rejection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with established CAN who are receiving triple immunosuppressive therapy with a CNI, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and an antimetabolite, we suggest minimization of CNI therapy (using a lower-than-standard dose) rather than withdrawal (gradual elimination of the CNI) or conversion (switching from a CNI to an alternate immunosuppressive agent) of CNI therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We minimize CNI therapy by targeting lower trough levels (such as 3.5 to 5 ng/mL for <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and 75 to 125 ng/mL for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>).</p><p></p><p class="bulletIndent2">For those who are receiving <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> as part of their maintenance immunosuppression, we suggest switching to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> rather than continuing azathioprine (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with established CAN, we suggest<strong> not </strong>withdrawing glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other supportive measures to help prevent the development of CAN include aggressive control of blood pressure and hyperlipidemia. (See <a class="local">'Other supportive measures'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.</a></li><li><a class="nounderline abstract_t">Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.</a></li><li><a class="nounderline abstract_t">Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.</a></li><li><a class="nounderline abstract_t">Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67:341.</a></li><li><a class="nounderline abstract_t">Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.</a></li><li><a class="nounderline abstract_t">Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857.</a></li><li><a class="nounderline abstract_t">Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68:1200.</a></li><li><a class="nounderline abstract_t">Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69:2357.</a></li><li><a class="nounderline abstract_t">Vadivel N, Tullius SG, Chandraker A. Chronic allograft nephropathy. Semin Nephrol 2007; 27:414.</a></li><li><a class="nounderline abstract_t">Monaco AP, Burke JF Jr, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33:150.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.</a></li><li><a class="nounderline abstract_t">Gouldesbrough DR, Axelsen RA. Arterial endothelialitis in chronic renal allograft rejection: a histopathological and immunocytochemical study. Nephrol Dial Transplant 1994; 9:35.</a></li><li><a class="nounderline abstract_t">Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.</a></li><li><a class="nounderline abstract_t">Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17:881.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326.</a></li><li><a class="nounderline abstract_t">Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11:698.</a></li><li><a class="nounderline abstract_t">Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16:3015.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428.</a></li><li><a class="nounderline abstract_t">Kim MY, Brennan DC. Therapies for Chronic Allograft Rejection. Front Pharmacol 2021; 12:651222.</a></li><li><a class="nounderline abstract_t">Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.</a></li><li><a class="nounderline abstract_t">Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32:582.</a></li><li><a class="nounderline abstract_t">Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46:266.</a></li><li><a class="nounderline abstract_t">Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl 1995; 50:S40.</a></li><li><a class="nounderline abstract_t">Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68:1.</a></li><li><a class="nounderline abstract_t">Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580.</a></li><li><a class="nounderline abstract_t">Sawinski D, Trofe-Clark J, Leas B, et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant 2016; 16:2117.</a></li><li><a class="nounderline abstract_t">Hricik DE, Formica RN, Nickerson P, et al. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. J Am Soc Nephrol 2015; 26:3114.</a></li><li><a class="nounderline abstract_t">Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514.</a></li><li><a class="nounderline abstract_t">Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77:244.</a></li><li><a class="nounderline abstract_t">Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77:252.</a></li><li><a class="nounderline abstract_t">Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81:845.</a></li><li><a class="nounderline abstract_t">Moreso F, Serón D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78:1064.</a></li><li><a class="nounderline abstract_t">Jevnikar A, Arlen D, Barrett B, et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation 2008; 86:953.</a></li><li><a class="nounderline abstract_t">Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77:215.</a></li><li><a class="nounderline abstract_t">Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.</a></li><li><a class="nounderline abstract_t">Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.</a></li><li><a class="nounderline abstract_t">Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257.</a></li><li><a class="nounderline abstract_t">Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.</a></li><li><a class="nounderline abstract_t">Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19:940.</a></li><li><a class="nounderline abstract_t">Artz MA, Hilbrands LB, Borm G, et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19:2852.</a></li><li><a class="nounderline abstract_t">Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73:783.</a></li><li><a class="nounderline abstract_t">O'Connell PJ, Zhang W, Menon MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 2016; 388:983.</a></li><li><a class="nounderline abstract_t">Friedewald JJ, Kurian SM, Heilman RL, et al. Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant 2019; 19:98.</a></li></ol></div><div id="topicVersionRevision">Topic 7359 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377384" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352710" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7871557" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Both alloantigen-dependent and -independent factors influence chronic allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610260" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8497913" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early versus late acute renal allograft rejection: impact on chronic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154032" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The impact of an acute rejection episode on long-term renal allograft survival (t1/2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551652" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Features of acute rejection that increase risk for chronic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868640" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical determinants of multiple acute rejection episodes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17616274" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915283" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787648" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Histopathologic findings associated with a chronic, progressive decline in renal allograft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909922" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Arterial endothelialitis in chronic renal allograft rejection: a histopathological and immunocytochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Banff 97 working classification of renal allograft pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467444" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668458" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The natural history of chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062418" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The histology of solitary renal allografts at 1 and 5 years after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120819" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic renal allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000139" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis and prevention of chronic kidney allograft loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33935762" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapies for Chronic Allograft Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110738" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk of renal allograft loss from recurrent glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774118" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933845" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8544435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term failure of renal transplants: adding insult to injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954891" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic renal allograft rejection: pathophysiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856798" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Strategies to improve long-term outcomes after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26990455" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925687" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16468960" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742989" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570006" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480175" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Baseline immunosuppression is associated with histological findings in early protocol biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852662" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742984" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936569" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845569" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035607" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481415" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15031353" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466882" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907428" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Angiotensin converting enzyme inhibition in chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27452608" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985559" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
